Impact of congestive heart failure treatment on peripheral microvascular tissue oxygenation

Congestive Heart Failure

Volumn 17, Issue 6, 2011, Pages 294-302

  Hogan, Christopher J ^a   Ward, Kevin R ^a,b   Pittman, Roland C ^a,b   Kontos, Michael C ^a,b   Thacker, Leroy R ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; INOTROPIC AGENT; NESIRITIDE; NITRATE;

ABSORPTION SPECTROSCOPY; ADULT; ARTICLE; CARDIAC PATIENT; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TISSUE OXYGENATION;

FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; OXYGEN CONSUMPTION; OXYHEMOGLOBINS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPECTRUM ANALYSIS; VASCULAR RESISTANCE;

EID: 82055185080     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00225.x     Document Type: Article

References (33)

1. De Backer D, Creteur J, Dubois MJ, et al. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J. 2004;147:91-99.
2. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-433.
3. Hogan CJ, Hess ML, Ward KR, et al. Quantitative tissue hemoglobin oxygen saturation measurement in decompensated heart failure. J Cardiothorac Ren Res. 2006;1:153-157.
4. den Uil CA, Caliskan K, Lagrand WK, et al. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Med. 2009;35:1893-1899.
5. Di Bari M, Pozzi C, Cavallini MC, et al. The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe dicomano study. J Am Coll Cardiol. 2004;44:1601-1608.
6. Nazerian P, Vanni S, Zanobetti M, et al. Diagnostic accuracy of emergency Doppler echocardiography for identification of acute left ventricular heart failure in patients with acute dyspnea: comparison with Boston criteria and N-terminal prohormone brain natriuretic peptide. Acad Emerg Med. 2010;17:18-26.
7. Guyton AC. The Systemic Circulation, 6th ed. Philadelphia, PA: W.B. Saunders; 1981.
8. Hogan C, Ward K, Hess M. Peripheral tissue oxygen extraction abnormalities persist in acutely decompensated heart failure after emergency department treatment. Acad Emerg Med. 2007;14:S116.
9. Hogan C, Ward K, Hess M. Microvascular tissue perfusion in stable versus decompensated heart failure. Acad Emerg Med. 2005;12:56.
10. Hogan CJ, Hess ML, Ward KR, Kontos ML. Microvascular hypoperfusion persists prior to discharge in patients admitted for decompensated heart failure. Crit Care Med. 2005;33:A54.
11. Hogan C, Ward K, Hess M. "Microvascular Tissue Perfusion Assessment Predicts Adverse Outcomes in Heart Failure" (poster presentation) presented at the American Heart Association Resuscitation Science Symposium in Dallas, TX on November 11, 2005.
12. Beilman GJ, Groehler KE, Lazaron V, Ortner JP. Near-infrared spectroscopy measurement of regional tissue oxyhemoglobin saturation during hemorrhagic shock. Shock. 1999;12:196-200.
13. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
14. Hogan CJ, Hess ML, Ward KR, Gennings C. The utility of microvascular perfusion assessment in heart failure: a pilot study. J Cardiac Fail. 2005;11:713-719.
15. Gheorghiade M, Adams FK Jr, Gattis WA, et al. Surrogate end points in heart failure trials. Am Heart J. 2003;145:S67-S70.
16. Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med. 2003;4(suppl 7):S13-S20.
17. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21:669-674.
18. Emerman CL, DeMarco T, Costanzo M, Peacock WF. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Cardiac Fail. 2004;10:S116-S117.
19. Smithline HA, Caglar S, Blank FS. Physician vs patient assessment of dyspnea during acute decompensated heart failure. Congest Heart Fail. 2010;16:60-64.
20. Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med. 2006;47:13-18.
21. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J. 2003;145:S26-S33.
22. Chang AM, Maisel AS, Hollander JE. Diagnosis of heart failure. Heart Fail Clin. 2009;5:25-35, vi.
23. Ander DS, Jaggi M, Rivers E, et al. Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Am J Cardiol. 1998;82:888-891.
24. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-385.
25. Singer AJ, Birkhahn RH, Guss D, et al. Rapid emergency department heart failure outpatients trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail. 2009;2:287-293.
26. Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005;294:1944-1956.
27. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-392.
28. Schneider HG, Lam L, Lokuge A, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med. 2009;150:365-371.
29. Jessup MD, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119(14):1977-2016.
30. Hamilton RJ, Carter WA, Gallagher EJ. Rapid improvement of acute pulmonary edema with sublingual captopril. Acad Emerg Med. 1996;3:205-212.
31. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010;31:832-841.
32. Smithline HA, Caglar S, Blank FSJ. Assessing validity by comparing transition and static measures of dyspnea in patients with acute decompensated heart failure. Congest Heart Fail. 2010;16:202-207.
33. Yancy CW. Heart failure in African Americans: unique etiology and pharmacologic treatment responses. J Natl Med Assoc. 2003;95:1-9, quiz 10-2.